Is Divi's Laboratories the Best Stock in Its Sector? A Look at the Numbers

Is Divi's Laboratories the best stock in its sector? The stock trades on the NSE at Rs 9,280 as of 13 October 2026, within its 52-week range of Rs 5,647.50 to Rs 9,740.00. Divi's Laboratories Ltd, headquartered in Hyderabad, is a pharmaceutical manufacturer known for active pharmaceutical ingredients and custom synthesis for global drug makers.

Divi's Laboratories sits in the Healthcare sector, and its 15.32% ROE and 85.12x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Divi's Laboratories

Divi's Laboratories Ltd, headquartered in Hyderabad, is a pharmaceutical manufacturer known for active pharmaceutical ingredients and custom synthesis for global drug makers. Generic active ingredients, custom synthesis and nutraceutical ingredients form its revenue base. The stock trades about 5 percent below its 52-week high and about 64 percent above its 52-week low. At a market capitalisation of Rs 2,48,983 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Divi's Laboratories the Best Stock in Its Sector?

Divi's Laboratories' case rests on returns and a debt-free balance sheet rather than on cheap valuation, with a 15.32% ROE. Divi's 85.12x P/E is more than double the 36.69x Industry P/E, while its 15.32% ROE is higher than both Dr. Reddy's and Sun Pharma, so the premium is partly supported by returns but leaves little room for error.

Metric	Divi's Laboratories
CMP (NSE)	Rs 9,280.50
52-Week High / Low	Rs 9,740.00 / Rs 5,647.50
Market Cap	Rs 2,48,983 Cr
P/E (TTM) vs Industry P/E	85.12x vs 36.69x
P/B	14.85
ROE	15.32%
EPS (TTM)	Rs 110.18
Dividend Yield	0.32%
Debt to Equity	0.00

Compare Divi's Laboratories Against Other Healthcare Sector Stocks

How Divi's Laboratories Compares Against Its Healthcare Sector Peers

The table below sets Divi's Laboratories against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Divi's Laboratories	2,48,983	85.12	15.32%	0.00
Dr. Reddy's Laboratories	1,02,707	32.26	11.07%	0.20
Sun Pharmaceutical Industries	4,22,067	34.83	13.74%	0.06
Peer average (2 companies)	-	33.55	12.41%	0.13

Against this peer set, Divi's Laboratories's 15.32% ROE is above the 12.41% peer average, and its P/E of 85.12x runs above the peer average of 33.55x. Divi's 85.12x P/E is more than double the 36.69x Industry P/E, while its 15.32% ROE is higher than both Dr. Reddy's and Sun Pharma, so the premium is partly supported by returns but leaves little room for error.

What Makes Divi's Laboratories Worth Watching in Healthcare

• Debt free: A debt to equity ratio of 0.00 compares with 0.20 for Dr. Reddy's and 0.06 for Sun Pharma.
• Higher returns: A 15.32% ROE is higher than Dr. Reddy's at 11.07% and Sun Pharma at 13.74%.
• Premium valuation: An 85.12x P/E against a 36.69x Industry P/E prices in strong future growth.

Divi's Laboratories Valuation: Is It Justified?

Divi's 85.12x P/E is more than double the 36.69x Industry P/E, while its 15.32% ROE is higher than both Dr. Reddy's and Sun Pharma, so the premium is partly supported by returns but leaves little room for error. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Sun Pharma the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Divi's Laboratories and other Healthcare sector stocks.

How to Track Divi's Laboratories Before You Invest

Before deciding whether Divi's Laboratories deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Divi's Laboratories to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Divi's Laboratories earns a place in the best stock in its sector conversation on the strength of a 15.32% ROE and a P/E of 85.12x against a 36.69x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Divi's Laboratories the best stock in its sector?

Ans. Divi's Laboratories has a 15.32% ROE and trades at 85.12x P/E against a 36.69x Industry P/E, and compares above the peer average ROE of 12.41% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Divi's Laboratories?

Ans. Divi's Laboratories was trading at Rs 9,280.50 on the NSE as of 13 October 2026, within its 52-week range of Rs 5,647.50 to Rs 9,740.00.

What sector does Divi's Laboratories belong to?

Ans. Divi's Laboratories is classified under the Healthcare sector on Univest.

How does Divi's Laboratories compare to its sector peers on P/E?

Ans. Divi's Laboratories's P/E of 85.12x is above the 33.55x average of the 2 named peers compared in this article.

What is Divi's Laboratories's return on equity?

Ans. Divi's Laboratories reported a return on equity of 15.32%, which is above the 12.41% average of its named peers in this comparison.

Should I invest in Divi's Laboratories based on its sector position?

Ans. Divi's Laboratories's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Divi's Laboratories the best stock in its sector?", "acceptedAnswer": {"@type": "Answer", "text": "Divi's Laboratories has a 15.32% ROE and trades at 85.12x P/E against a 36.69x Industry P/E, and compares above the peer average ROE of 12.41% in this article's named comparison, so the answer depends on what an investor is prioritising."}}, {"@type": "Question", "name": "What is the current share price of Divi's Laboratories?", "acceptedAnswer": {"@type": "Answer", "text": "Divi's Laboratories was trading at Rs 9,280.50 on the NSE as of 13 October 2026, within its 52-week range of Rs 5,647.50 to Rs 9,740.00."}}, {"@type": "Question", "name": "What sector does Divi's Laboratories belong to?", "acceptedAnswer": {"@type": "Answer", "text": "Divi's Laboratories is classified under the Healthcare sector on Univest."}}, {"@type": "Question", "name": "How does Divi's Laboratories compare to its sector peers on P/E?", "acceptedAnswer": {"@type": "Answer", "text": "Divi's Laboratories's P/E of 85.12x is above the 33.55x average of the 2 named peers compared in this article."}}, {"@type": "Question", "name": "What is Divi's Laboratories's return on equity?", "acceptedAnswer": {"@type": "Answer", "text": "Divi's Laboratories reported a return on equity of 15.32%, which is above the 12.41% average of its named peers in this comparison."}}, {"@type": "Question", "name": "Should I invest in Divi's Laboratories based on its sector position?", "acceptedAnswer": {"@type": "Answer", "text": "Divi's Laboratories's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor."}}]}